ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution

Over the past decade, we have seen a significant change in modern approaches in the first-line treatment of chronic lymphocytic leukemia (CLL). The CLL-10 study data established the FCR regimen as the treatment of choice for younger patients with limited comorbidities, while for patients older than...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Irina V. Poddubnaya, Lyubov S. Al-Radi, Tatyana E. Byalik, Kamil D. Kaplanov, Valentina Z. Molostvova, Evgeniy A. Nikitin, Tatyana I. Pospelova, Vadim V. Ptushkin, Olga S. Samoilova, Elena A. Stadnik, Gayane S. Tumyan
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2020
Materias:	chronic lymphocytic leukemia bruton’s tyrosine kinase inhibitors immunochemotherapy targeted therapy acalabrutinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/67aed2307be24cdebf0808eebbc30d52
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution

Ejemplares similares